Through its issuance of recommendations and regulatory decisions concerning medical products, the US Food and Drug Administration (FDA) typically considers the “unmet medical need” surrounding a particular disease or condition. In the most extreme circumstances, as with many rare diseases, FDA-approved therapies may not be available. There are also numerous contexts, however, in which treatments are approved, but a need still exists for refinement to better target the patient population – such is the case for heart failure (HF) drugs. Deborah Komlos at Clarivate, explains more about the treatment horizon for heart failure patients.